Advanced hybrid closed-loop therapy has transformed type 1 diabetes management, enabling sustained glycemic control with reduced manual input. Findings from a real-world analysis in Europe, the Middle East, and Africa were presented at the European Association for the Study of Diabetes Conference 2025.

Data from 1,145 users aged 16 years and older demonstrated immediate improvement in glycemic control, with average time in range rising to 78.6% and remaining stable over three years. Insulin delivered by the system increased steadily, while user-delivered insulin decreased, reflecting a lower burden on patients. The proportion of users adopting recommended optimal settings grew over time, highlighting increased trust in the system.

These results illustrate the long-term reliability and adaptability of advanced hybrid closed-loop systems. Reduced user effort combined with consistent glycemic outcomes underscores the potential of automated insulin delivery to improve both patient experience and clinical outcomes in type 1 diabetes.